Emerging Endoscopic Strategies in Obesity Management Innovations and Future Perspectives
DOI:
https://doi.org/10.12775/QS.2025.41.60288Keywords
aspiration therapies, endoscopic treatment of obesity, ESG, IGB, DJBSAbstract
Emerging endoscopic strategies are revolutionizing the treatment of obesity by offering a less invasive alternative to traditional bariatric surgery. Conventional approaches, including lifestyle modifications and pharmacotherapy, often result in only moderate weight loss, while surgical interventions, despite their high efficacy, carry a significant risk of short- and long-term complications. This paper provides a comprehensive overview of current endoscopic modalities, such as various intragastric balloons (Orbera, ReShape, Obalon, Spatz3, Ellipse, Heliosphere), endoscopic sleeve gastroplasty, aspiration therapies, and duodenal–jejunal bypass sleeves. These techniques work by reducing gastric volume, modulating gut hormone secretion, and delaying gastric emptying, thereby enhancing satiety and promoting sustained weight loss. The review emphasizes that while early results are promising, demonstrating significant weight reduction and metabolic improvements with lower complication rates than surgical methods, further long-term studies are required to fully establish their efficacy and safety profile. Endoscopic bariatric interventions are positioned as a valuable addition to the obesity treatment armamentarium, particularly for patients who are not ideal candidates for surgery or who seek reversible treatment options.
References
[1] World Health Organisation. Obesity and Overweight. World Health Organisation. Published June 9, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
[2] Nadwaga i otyłość u dorosłych. www.mp.pl. Accessed February 22, 2023. https://www.mp.pl/nadwaga-i-otylosc/wytyczne/246952.
[3] Operacje bariatryczne: są nowe wytyczne dot. kwalifikacji do zabiegów. pulsmedycyny.pl. Accessed February 22, 2023. https://pulsmedycyny.pl/operacje-bariatryczne-sa-nowe-wytyczne-dot-kwalifikacji-do-zabiegow-1167427.
[4] Estimate of Bariatric Surgery Numbers, 2011-2017 | American Society for Metabolic and Bariatric Surgery. American Society for Metabolic and Bariatric Surgery. Published June 26, 2018. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers.
[5] Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters. Obesity Surgery. Published online January 12, 2021. doi:https://doi.org/10.1007/s11695-020-05207-7.
[6] Courcoulas A, Coley RY, Clark JM, et al. Interventions and Operations 5 Years After Bariatric Surgery in a Cohort From the US National Patient-Centered Clinical Research Network Bariatric Study. JAMA Surgery. 2020;155(3):194. doi:https://doi.org/10.1001/jamasurg.2019.5470.
[7] Mathus-Vliegen EMH, de Groot GH. Fasting and Meal-Induced CCK and PP Secretion Following Intragastric Balloon Treatment for Obesity. Obesity Surgery. 2012;23(5):622-633. doi:https://doi. org/10.1007/s11695-012-0834-6.
[8] Laing P, Pham T, Taylor LJ, Fang J. Filling the Void: A Review of Intragastric Balloons for Obesity. Digestive Diseases and Sciences. 2017;62(6):1399-1408. doi:https://doi.org/10.1007/ s10620-017-4566-2.
[9] Glass J, Chaudhry A, Zeeshan MS, Ramzan Z. New Era: Endoscopic treatment options in obesity–a paradigm shift. World Journal of Gastroenterology. 2019;25(32):4567-4579. doi:https://doi. org/10.3748/wjg.v25.i32.4567.
[10] Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, et al. Endoscopic bariatric therapies. Gastrointestinal Endoscopy. 2015;81(5):1073- 1086. doi:https://doi.org/10.1016/j.gie.2015.02.023.
[11] Genco A, Maselli R, Frangella F, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surgical Endoscopy. 2015;29(8):2339- 2343. doi:https://doi.org/10.1007/s00464-014-3957-0.
[12] Ashrafian H, Monnich M, Braby TS, Smellie J, Bonanomi G, Efthimiou E. Intragastric balloon outcomes in super-obesity: a 16-year city center hospital series. Surgery for Obesity and Related Diseases. 2018;14(11):1691-1699. doi:https://doi.org/10.1016/j.soard.2018.07.010.
[13] Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obesity Surgery. 2012;22(6):896-903. doi:https://doi.org/10.1007/s11695-012-0607-2.
[14] Ways to Lose Weight Without Surgery | Learn About Gastric Balloon. Orbera.com. Published 2022. Accessed February 22, 2023. https://www.orbera.com/uk-ireland/about-orbera.
[15] Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surgery for Obesity and Related Diseases. 2015;11(4):874-881. doi:https://doi.org/10.1016/j.soard.2014.12.006.
[16] Agnihotri A, Xie A, Bartalos C, et al. Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight Loss. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association. 2018;16(7):1081- 1088.e1. doi:https://doi.org/10.1016/j.cgh.2018.02.026.
[17] Weight M. Orbera® Managed Weight Loss System. Orbera.com. Published 2018. Accessed February 22, 2023. https://www.orbera.com/reshape/.
[18] Health C for D and R. UPDATE: Potential Risks with Liquid-filled Intragastric Balloons - Letter to Health Care Providers. FDA. Published online August 22, 2022. Accessed February 22, 2023. https://www.fda.gov/medical-devices/letters-health-care-pro viders/update-potential-risks-liquid-filled-intragastric-balloons-let ter-health-care-providers.
[19] Stavrou G, Shrewsbury A, Kotzampassi K. Six intragastric balloons: Which to choose? World Journal of Gastrointestinal Endoscopy. 2021;13(8):238-259. doi:https://doi.org/10.4253/wjge.v13.i8.238.
[20] Sullivan S, Swain J, Woodman G, et al. Randomized sham-con trolled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surgery for Obesity and Related Diseases. 2018;14(12):1876-1889. doi:https://doi.org/10.1016/j.soard.2018.09.486.
[21] Genco A, Dellepiane D, Baglio G, et al. Adjustable intragastric balloon vs non-adjustable intragastric balloon: case-control study on complications, tolerance, and efficacy. Obesity Surgery. 2013;23(7):953- 958. doi:https://doi.org/10.1007/s11695-013-0891-5.
[22] Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obesity Surgery. 2011;21(10):1499-1507. doi:https://doi.org/10.1007/s11695-011-0424-z.
[23] Health C for D and R. Spatz3 Adjustable Balloon System - P190012. FDA. Published online May 12, 2022. https://www.fda.gov/medical-devices/recently-approved-devices/ spatz3-adjustable-balloon-system-p190012.
[24] Choi SJ, Choi HS. Various Intragastric Balloons Under Clinical Investigation. Clinical Endoscopy. 2018;51(5):407-415. doi:https:// doi.org/10.5946/ce.2018.140.
[25] Jamal MH, Almutairi R, Elabd R, AlSabah SK, Alqattan H, Altaweel T. The Safety and Efficacy of Procedureless Gastric Balloon: a Study Examining the Effect of Elipse Intragastric Balloon Safety, Short and Medium Term Effects on Weight Loss with 1-Year Follow-Up Post-removal. Obesity Surgery. 2019;29(4):1236-1241. doi:https://doi.org/10.1007/s11695-018-03671-w.
[26] Ienca R, Al Jarallah M, Caballero A, et al. The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients. Obesity Surgery. 2020;30(9):3354-3362. doi:https:// doi.org/10.1007/s11695-020-04539-8.
[27] Usuy E, Brooks J. Response Rates with the Spatz3 Adjustable Balloon. Obesity Surgery. 2017;28(5):1271-1276. doi:https://doi.org/10.1007/s11695-017-2994-x.
[28] Genco A, Ernesti I, Ienca R, et al. Safety and Efficacy of a New Swallowable Intragastric Balloon Not Needing Endoscopy: Early Italian Experience. Obesity Surgery. 2018;28(2):405-409. doi:https://doi. org/10.1007/s11695-017-2877-1.
[29] Machytka E, Chuttani R, Bojkova M, et al. ElipseTM, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study. Obesity Surgery. 2015;26(3):512-516. doi:https://doi.org/10.1007/ s11695-015-1783-7.
[30] Espinet-Coll E, Nebreda-Durán J, Gómez-Valero JA, et al. Current endoscopic techniques in the treatment of obesity. Revista Espanola De Enfermedades Digestivas. 2012;104(2):72-87. doi:https://doi. org/10.4321/s1130-01082012000200006.
[31] Giardiello C, Borrelli A, Silvestri E, Antognozzi V, Iodice G, Lorenzo M. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obesity Surgery. 2012;22(12):1916-1919. doi:https://doi.org/10.1007/s11695-012-0786-x.
[32] Trande P, Mussetto A, Mirante VG, et al. Efficacy, tolerance and safety of new intragastric air-filled balloon (Heliosphere BAG) for obesity: the experience of 17 cases. Obesity Surgery. 2010;20(9):1227- 1230. doi:https://doi.org/10.1007/s11695-008-9786-2.
[33] Forestieri P, De Palma GD, Formato A, et al. Heliosphere Bag in the treatment of severe obesity: preliminary experience. Obesity Surgery. 2006;16(5):635-637. doi:https://doi.org/10.1381/096089206776945156.
[34] Mion F, Gincul R, Roman S, et al. Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study. Obesity Surgery. 2007;17(6):764- 769. doi:https://doi.org/10.1007/s11695-007-9141-z.
[35] Kumar N. Endoscopic therapy for weight loss: Gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World Journal of Gastrointestinal Endoscopy. 2015;7(9):847. doi:https://doi.org/10.4253/wjge.v7.i9.847.
[36] Tsesmeli N, Coumaros D. Review of endoscopic devices for weight reduction: old and new balloons and implantable prostheses. Endoscopy. 2009;41(12):1082-1089. doi:https://doi.org/10.1055/s-0029-1215269.
[37] Lecumberri E, Krekshi W, Matía P, et al. Effectiveness and safety of air-filled balloon Heliosphere BAG® in 82 consecutive obese patients. Obesity Surgery. 2011;21(10):1508-1512. doi:https://doi.org/10.1007/s11695-010-0314-9.
[38] Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. Clinical Gastroenterology and Hepatology. 2017;15(1):37-43.e1. doi:https://doi.org/10.1016/j. cgh.2015.12.030.
[39] Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and class 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet (London, England). 2022;400(10350):441-451. doi:https://doi.org/10.1016/ S0140-6736(22)01280-6.
[40] Sullivan S, Swain JM, Woodman G, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity (Silver Spring, Md). 2017;25(2):294-301. doi:https://doi.org/10.1002/ oby.21702.
[41] Kumar N, Sullivan S, Thompson C. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;Volume 10:311-316. doi:https://doi.org/10.2147/dmso.s95118.
[42] Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. The American Journal of Gastroenterology. 2017;112(3):447-457. doi:https://doi. org/10.1038/ajg.2016.500.
[43] Chirurgia po Dyplomie - Nowe metody endoskopowego leczenia otyłości olbrzymiej. podyplomie.pl. Accessed February 23, 2023. https://podyplomie.pl/chirurgia/15762.
[44] Glass J, Chaudhry A, Zeeshan MS, Ramzan Z. New Era: Endoscopic treatment options in obesity–a paradigm shift. World Journal of Gastroenterology. 2019;25(32):4567-4579. doi:https://doi. org/10.3748/wjg.v25.i32.4567.
[45] Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointestinal Endoscopy. 2015;82(3):425-438.e5. doi:https://doi.org/10.1016/j.gie.2015.03.1964.
[46] de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic Duodenal– Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes. Obesity Surgery. 2013;23(9):1354-1360. doi:https://doi.org/10.1007/ s11695-013-0921-3.
[47] Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia. 2009;52(11):2270-2276. doi:https://doi. org/10.1007/s00125-009-1511-8.
[48] van Rijn S, Roebroek YGM, de Jonge C, Greve JWM, Bouvy ND. Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial. Obesity Surgery. 2019;29(4):1117-1121. doi:https://doi.org/10.1007/s11695-018-03659-6.
[49] Ruban A, Ashrafian H, Teare JP. The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss. Gastroenterology Research and Practice. 2018;2018:1-9. doi:https://doi. org/10.1155/2018/7823182.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aneta Rasińska, Piotr Rzyczniok, Weronika Rasińska, Anna Rzyczniok, Justyna Jachimczak, Justyna Matusik, Paulina Bala, Mateusz Kopczyński

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 77
Number of citations: 0